Ruben A Mesa

Ruben A Mesa

UNVERIFIED PROFILE

Are you Ruben A Mesa?   Register this Author

Register author
Ruben A Mesa

Ruben A Mesa

Publications by authors named "Ruben A Mesa"

Are you Ruben A Mesa?   Register this Author

100Publications

3587Reads

12Profile Views

Assessment of Quality of Life following Allogeneic Stem Cell Transplant for Myelofibrosis.

Biol Blood Marrow Transplant 2019 Nov 6;25(11):2267-2273. Epub 2019 Jul 6.

Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.07.001DOI Listing
November 2019

Proactive steps to optimize the management of polycythemia vera and myelofibrosis.

Authors:
Ruben A Mesa

Clin Adv Hematol Oncol 2019 Sep;17(9):475-477

Mays Cancer Center at UT Health San Antonio, MD Anderson Cancer Center, San Antonio, Texas.

View Article

Download full-text PDF

Source
September 2019

Development of a symptom assessment in patients with myelofibrosis: qualitative study findings.

Health Qual Life Outcomes 2019 Apr 11;17(1):61. Epub 2019 Apr 11.

Guy's and St. Thomas' NHS Foundation Trust, St. Thomas Hospital, Westminster Bridge Rd. Lambeth, London, SE1 7EH, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12955-019-1121-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6460742PMC
April 2019

Quality of life and symptom burden among myeloproliferative neoplasm patients: do symptoms impact quality of life?

Leuk Lymphoma 2019 02 22;60(2):402-408. Epub 2018 Jul 22.

a Section of Biostatistics , Mayo Clinic , Scottsdale , AZ , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2018.1480768DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6363896PMC
February 2019

Highlights in myeloproliferative neoplasms from the 60th American Society of Hematology Annual Meeting: commentary.

Authors:
Ruben A Mesa

Clin Adv Hematol Oncol 2019 01;17 Suppl 2(1):18-19

UT Health San Antonio Cancer Center, University of Texas Health Science Center, San Antonio, Texas.

View Article

Download full-text PDF

Source
January 2019

Managing myelofibrosis (MF) that "blasts" through: advancements in the treatment of relapsed/refractory and blast-phase MF.

Hematology Am Soc Hematol Educ Program 2018 11;2018(1):118-126

Mays Cancer Center, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2018.1.118DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6245993PMC
November 2018

Refining the management of polycythemia vera.

Authors:
Ruben A Mesa

Clin Adv Hematol Oncol 2018 Sep;16(9):587-589

UT Health San Antonio Cancer Center, University of Texas Health Science Center, San Antonio, Texas.

View Article

Download full-text PDF

Source
September 2018

Treatment With JAK Inhibitors in Myelofibrosis Patients Nullifies the Prognostic Impact of Unfavorable Cytogenetics.

Clin Lymphoma Myeloma Leuk 2018 05 2;18(5):e201-e210. Epub 2018 Mar 2.

University of Michigan Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2018.02.019DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5927833PMC
May 2018

Pacritinib and its use in the treatment of patients with myelofibrosis who have thrombocytopenia.

Future Oncol 2018 Apr 13;14(9):797-807. Epub 2017 Dec 13.

Hematology Oncology Division, UT Health San Antonio Cancer Center, 7979 Wurzbach Road, San Antonio, TX 78229, USA.

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/fon-2017-0494
Publisher Site
http://dx.doi.org/10.2217/fon-2017-0494DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6439520PMC
April 2018

SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis.

J Clin Oncol 2017 Dec 20;35(34):3844-3850. Epub 2017 Sep 20.

Ruben A. Mesa, Mayo Clinic Cancer Center, Scottsdale, AZ; Jean-Jacques Kiladjian, Saint-Louis Hospital (Assistance Publique-Hôpitaux de Paris) and Paris Diderot University, Paris, France; John V. Catalano, Frankston Hospital and Monash University, Melbourne, Victoria, Australia; Timothy Devos, University Hospital Leuven and Katholieke Universiteit Leuven, Leuven, Belgium; Miklos Egyed, Kaposi Mor Teaching Hospital, Kaposvar, Hungary; Andrzei Hellmann, Medical University of Gdańsk, Gdańsk, Poland; Donal McLornan, Guy's and St Thomas' National Health Service Foundation Trust, London, United Kingdom; Kazuya Shimoda, University of Miyazaki, Miyazaki, Japan; Elliott F. Winton, Emory University School of Medicine, Atlanta, GA; Wei Deng, Ronald L. Dubowy, and Julia D. Maltzman, Gilead Sciences, Foster City; Jason Gotlib, Stanford Cancer Institute, Stanford, CA; and Francisco Cervantes, Hospital Clinic, Institut D'Investigacions Biomèdiques August Pi I Sunyer, University of Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.73.4418
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.73.4418DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6553796PMC
December 2017

New guidelines from the NCCN for polycythemia vera.

Authors:
Ruben A Mesa

Clin Adv Hematol Oncol 2017 Nov;15(11):848-850

University of Texas Health Science Center, San Antonio, Texas.

View Article

Download full-text PDF

Source
November 2017

A phase 1 study of the Janus kinase 2 (JAK2) inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia.

Leuk Res 2017 10 31;61:89-95. Epub 2017 Aug 31.

University of Utah School of Medicine, Division of Hematology, 30 North 1900 East, Salt Lake City, UT 84132, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2017.08.010DOI Listing
October 2017

Approach to MPN Symptom Assessment.

Curr Hematol Malig Rep 2017 10;12(5):381-388

Division of Hematology and Medical Oncology, Mayo Clinic, 5777 E Mayo Blvd, Phoenix, AZ, 85054, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-017-0399-5DOI Listing
October 2017

The use and impact of Twitter at medical conferences: Best practices and Twitter etiquette.

Semin Hematol 2017 10 24;54(4):184-188. Epub 2017 Aug 24.

Aurora Research Institute, Aurora Health Care, Milwaukee, WI.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminhematol.2017.08.003DOI Listing
October 2017

Allogeneic Stem Cell Transplantation in Myelofibrosis.

Biol Blood Marrow Transplant 2017 Sep 10;23(9):1429-1436. Epub 2017 May 10.

Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, Arizona.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2017.05.007DOI Listing
September 2017

A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia.

Leuk Res 2017 09 30;60:11-17. Epub 2017 May 30.

Department of Clinical Haematology and Bone Marrow Transplantation, Royal Melbourne Hospital, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2017.05.002DOI Listing
September 2017

Development of a harmonized patient-reported outcome questionnaire to assess myelofibrosis symptoms in clinical trials.

Leuk Res 2017 08 12;59:26-31. Epub 2017 May 12.

Patient-Reported Outcome Consortium, Critical Path Institute, Tucson, AZ, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2017.05.012DOI Listing
August 2017

Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I.

Clin Lymphoma Myeloma Leuk 2017 08 12;17(8):479-487. Epub 2017 May 12.

Division of Cancer Medicine, Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2017.05.015DOI Listing
August 2017

Analysis of the Use and Impact of Twitter During American Society of Clinical Oncology Annual Meetings From 2011 to 2016: Focus on Advanced Metrics and User Trends.

J Oncol Pract 2017 07 17;13(7):e623-e631. Epub 2017 May 17.

The University of Texas MD Anderson Cancer Center, Houston, TX; Aurora Research Institute, Aurora Health Care, Milwaukee, WI; Mayo Clinic, Scottsdale AZ; US Department of Veterans Affairs; and Nephrology On-Demand Analytics, Charlotte, NC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.2017.021634DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508448PMC
July 2017

Myeloproliferative Neoplasms: Translating New Discoveries Into Better Outcomes, Better Quality of Life.

Oncology (Williston Park) 2017 07;31(7):521-9

View Article

Download full-text PDF

Source
July 2017

NCCN Debuts New Guidelines for Myeloproliferative Neoplasms.

Authors:
Ruben A Mesa

J Natl Compr Canc Netw 2017 05;15(5S):720-722

Presented by Ruben A. Mesa, MD, Division of Hematology and Medical Oncology, Mayo Clinic Cancer Center, Phoenix, Arizona.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2017.0083DOI Listing
May 2017

A phase 2 study of simtuzumab in patients with primary, post-polycythaemia vera or post-essential thrombocythaemia myelofibrosis.

Br J Haematol 2017 Mar 21;176(6):939-949. Epub 2017 Feb 21.

Stanford University School of Medicine/Stanford Cancer Institute, Stanford, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.14501DOI Listing
March 2017

The new NCCN guidelines for the management of myelofibrosis.

Authors:
Ruben A Mesa

Clin Adv Hematol Oncol 2017 Mar;15(3):193-195

Mayo Clinic Cancer Center, Arizona Cancer Coalition, Scottsdale, Arizona.

View Article

Download full-text PDF

Source
March 2017

Highlights in myeloproliferative neoplasms from the 2016 American Society of Hematology meeting: Commentary.

Authors:
Ruben A Mesa

Clin Adv Hematol Oncol 2017 02;15 Suppl 2(2):21-23

Mayo Clinic Cancer Center, Arizona Cancer Coalition, Scottsdale, Arizona.

View Article

Download full-text PDF

Source
February 2017

Individualizing Care for Patients With Myeloproliferative Neoplasms: Integrating Genetics, Evolving Therapies, and Patient-Specific Disease Burden.

Am Soc Clin Oncol Educ Book 2016 ;35:e324-35

From the Mayo Clinic Cancer Center, Phoenix, AZ; Division of Hematology, Department of Clinical and Experimental Medicine, University of Insubria, Varese, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_159322DOI Listing
January 2017

Ruxolitinib dose management as a key to long-term treatment success.

Int J Hematol 2016 Oct 27;104(4):420-9. Epub 2016 Aug 27.

Division of Cancer Medicine, Department of Leukemia, MD Anderson Cancer Center, University of Texas, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-016-2084-1DOI Listing
October 2016

Evaluating Elevated Hemoglobin-Reply.

JAMA 2016 09;316(10):1115

Mayo Clinic, Scottsdale, Arizona.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jama.2016.11335DOI Listing
September 2016

Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development.

Mediators Inflamm 2015 11;2015:284706. Epub 2015 Oct 11.

Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ 85054, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2015/284706DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4619953PMC
August 2016

Recent advances in the management of myelofibrosis.

Authors:
Ruben A Mesa

Clin Adv Hematol Oncol 2016 Aug;14(8):597-9

Mayo Clinic Cancer Center, Arizona Cancer Coalition, Scottsdale, Arizona.

View Article

Download full-text PDF

Source
August 2016

Emerging drugs for the treatment of myelofibrosis.

Expert Opin Emerg Drugs 2015 8;20(4):663-78. Epub 2015 Jul 8.

b 2 Mayo Clinic, Division of Hematology and Oncology, Department of Hematology and Medical Oncology , 13400 E Shea Blvd, Scottsdale, AZ, USA +1 480 301 8335 ; +1 480 301 4675 ;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14728214.2015.1061502DOI Listing
July 2016

Elevated Hemoglobin or Hematocrit Level.

JAMA 2016 May 24-31;315(20):2225-6

Mayo Clinic, Scottsdale, Arizona.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jama.2016.2435DOI Listing
June 2016

Comprehensively understanding fatigue in patients with myeloproliferative neoplasms.

Cancer 2016 Feb 15;122(3):477-85. Epub 2015 Dec 15.

Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, Arizona.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.29753DOI Listing
February 2016

Hormonal and Reproductive Factors and Risk of Myeloproliferative Neoplasms in Postmenopausal Women.

Cancer Epidemiol Biomarkers Prev 2016 Jan 12;25(1):151-7. Epub 2015 Nov 12.

Division of Epidemiology, Department of Health Sciences Research, College of Medicine, Mayo Clinic, Rochester, Minnesota.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1055-9965.EPI-15-0613DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4713297PMC
January 2016

Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease.

J Clin Oncol 2016 Jan 23;34(2):151-9. Epub 2015 Nov 23.

Holly Geyer, Robyn Scherber, Heidi Kosiorek, Amylou C. Dueck, and Ruben A. Mesa, Mayo Clinic, Scottsdale, AZ; Jean-Jacques Kiladjian, Hospital Saint-Louis, Paris; Francoise Boyer, Centre Hospitalier Universitaire, Angers; Gabriel Etienne, Institut Bergonie, Bordeaux; Jean-Christophe Ianotto, Centre Hospitalier Universitaire, Brest; Dana Ranta, Centre Hospitalier Universitaire, Grenoble; Lydia Roy, Centre Hospitalier Universitaire, Poitiers; Jean-Yves Cahn, Centre Hospitalier Universitaire, Grenoble, France; Zhijian Xiao, Zefeng Xu, Yue Zhang, Xiujuan Sun, Junqing Xu, and Peihong Zhang, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China; Stefanie Slot and Sonja Zweegman, VU University Medical Center, Amsterdam; Peter A.W. te Boekhorst, Erasmus Medical Center, Rotterdam; Suzan Commandeur, Leiden University Medical Center, Leiden; Harry Schouten, Maastricht University Medical Center, Maastricht, the Netherlands; Frederico Sackmann, Fundaleu, Buenos Aires, Argentina; Ana Kerguelen Fuentes and Dolores Hernández-Maraver, University Hospital La Paz, Madrid; Carlos Besses, Hospital del Mar; Francisco Cervantes, University of Barcelona, Barcelona, Spain; Konstanze Döhner and Frank Stegelmann, University Hospital of Ulm; Karin Bonatz and Andreas Reiter, Universitätsmedizin Mannheim, Mannheim; Heike L. Pahl, University Hospital Freiburg, Freiburg; Martin Griesshammer, Johannes Wesling Klinikum Minden, Germany; Claire N. Harrison and Deepti Radia, Guy's and St Thomas NHS Foundation Trust; Robert Peter Gale, Imperial College, London, United Kingdom; Pablo Muxi, Hospital Británico, Montevideo, Uruguay; Peter L. Johansson and Bjorn Andreasson, NU Hospital Organization, Uddevalla; Gunnar Birgegard, University Hospital, Uppsala; Jan Samuelsson, Stockholm South Hospital, Stockholm, Sweden; Alessandro Rambaldi, Tiziano Barbui, and Maria L. Ferrari, Ospedali Riuniti di Bergamo, Bergamo; Giovanni Barosi, IRCCS Policlinico S. Matteo Foundation; Franc

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.62.9337DOI Listing
January 2016

The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemia.

J Hematol Oncol 2015 Oct 20;8:114. Epub 2015 Oct 20.

Division of Hematology and Medical Oncology, Mayo Clinic/Mayo Clinic Cancer Center, 13400 E. Shea Boulevard, Scottsdale, AZ, 85259, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13045-015-0211-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4615363PMC
October 2015

Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis.

Leuk Lymphoma 2015 Jul 17;56(7):2092-7. Epub 2015 Feb 17.

Department of Leukemia, The University of Texas MD Anderson Cancer Center , Houston, TX , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2014.984703DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4919663PMC
July 2015

Reducing symptom burden in patients with myeloproliferative neoplasms in the era of Janus kinase inhibitors.

Leuk Lymphoma 2015 Jul 17;56(7):1989-99. Epub 2015 Mar 17.

Mayo Clinic , Scottsdale, AZ , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2014.983098DOI Listing
July 2015

Survival and new cancers with myeloproliferative neoplasms.

Lancet Haematol 2015 Jul 11;2(7):e272-3. Epub 2015 Jun 11.

Mayo Clinic, Hematology and Oncology, Scottsdale, AZ 85259, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2352-3026(15)00109-XDOI Listing
July 2015

Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms.

J Natl Compr Canc Netw 2015 Apr;13(4):424-34

From Northwestern University Feinberg School of Medicine, Chicago, Illinois; Stanford Cancer Institute, Stanford University, Stanford, California; Duke Cancer Institute, Duke University, Durham, North Carolina; University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan; University of California, San Francisco, San Francisco, California; Johns Hopkins University School of Medicine, Baltimore, Maryland; Moores Cancer Center, UC San Diego, San Diego, California; University of Colorado Cancer Center, Aurora, Colorado; Fred Hutchinson Cancer Research Center, Seattle, Washington; Dana Farber Cancer Institute, Boston, Massachusetts; Memorial Sloan Kettering Cancer Center, New York; New York; Moffitt Cancer Center and Research Institute, Tampa, Florida; The Ohio State University, Columbus, Ohio; Fred & Pamela Buffett Cancer Center, Omaha, Nebraska; Fox Chase Cancer Center, Philadelphia, Pennsylvania; Roswell Park Cancer Institute, Buffalo, New York; Washington University-Siteman Cancer Center, St Louis, Missouri; St. Jude Children's Research Hospital, Memphis, Tennessee; University of Alabama at Birmingham, Birmingham, Alabama; Vanderbilt-Ingram Cancer Center, Nashville, Tennessee; Yale University School of Medicine; New Haven, Connecticut; University of Utah, Salt Lake City, Utah; University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan; City of Hope Cancer Center, Los Angeles, California; The University of Texas MD Anderson Cancer Center, Houston, Texas; and Mayo Clinic Cancer Center, Scottsdale, Arizona.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2015.0058DOI Listing
April 2015

Profile of pomalidomide and its potential in the treatment of myelofibrosis.

Ther Clin Risk Manag 2015 2;11:549-56. Epub 2015 Apr 2.

Division of Hematology and Medical Oncology, Mayo Clinic Arizona, Scottsdale, AZ, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/TCRM.S69211DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4397931PMC
April 2015

Quality of life in MPN comes of age as a therapeutic target.

Curr Hematol Malig Rep 2014 Dec;9(4):324-30

Mayo Clinic, 13400 E. Shea Blvd, Scottsdale, AZ, 85259, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-014-0239-9DOI Listing
December 2014

Therapy for myeloproliferative neoplasms: when, which agent, and how?

Hematology Am Soc Hematol Educ Program 2014 Dec 18;2014(1):277-86. Epub 2014 Nov 18.

Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ.

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/content/early/2014/12/02/blood-2
Web Search
http://www.asheducationbook.org/cgi/doi/10.1182/asheducation
Publisher Site
http://dx.doi.org/10.1182/asheducation-2014.1.277DOI Listing
December 2014

Letter to Our Readers.

Authors:
Ruben A Mesa

Am Health Drug Benefits 2014 Oct;7(7 Suppl 3):S35

Professor and Chair, Division of Hematology and Medical Oncology, Deputy Director, Mayo Clinic Cancer Center, Professor of Medicine, Scottsdale, Arizona.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4639939PMC
October 2014

The future of JAK inhibition in myelofibrosis and beyond.

Blood Rev 2014 Sep 28;28(5):189-96. Epub 2014 Jun 28.

Mayo Clinic Cancer Center, Phoenix, AZ, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.blre.2014.06.002DOI Listing
September 2014

Janus kinase inhibitors for the treatment of myeloproliferative neoplasms.

Expert Opin Pharmacother 2014 Jun 25;15(9):1265-76. Epub 2014 Apr 25.

Mayo Clinic, Division of Hematology and Medical Oncology , Arizona , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14656566.2014.913024DOI Listing
June 2014

Assessing disease burden in patients with classic MPNs.

Best Pract Res Clin Haematol 2014 Jun 18;27(2):107-19. Epub 2014 Jul 18.

Division of Hematology and Medical Oncology, Mayo Clinic Cancer Center, Mayo Clinic, 13400 East Shea Boulevard, Scottsdale, AZ 85259, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.beha.2014.07.006DOI Listing
June 2014

Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union.

Eur J Haematol 2014 Apr 3;92(4):289-97. Epub 2014 Feb 3.

Oncology-Global Evidence and Value Development, Medical Affairs, Chilly-Mazarin, France, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.12256DOI Listing
April 2014

Targeting hedgehog signaling in myelofibrosis and other hematologic malignancies.

J Hematol Oncol 2014 Mar 5;7:18. Epub 2014 Mar 5.

Mayo Clinic Cancer Center, NCI Designated Comprehensive Cancer Center, 13400 E, Shea Blvd, Scottsdale, AZ 85259, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1756-8722-7-18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3975838PMC
March 2014

The new landscape of therapy for myelofibrosis.

Curr Hematol Malig Rep 2013 Dec;8(4):325-32

Division of Hematology and Medical Oncology, Mayo Clinic Cancer Center, Mayo Clinic, 13400 East Shea Boulevard, Scottsdale, AZ, 85259, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-013-0178-xDOI Listing
December 2013

Ruxolitinib for myelofibrosis--an update of its clinical effects.

Clin Lymphoma Myeloma Leuk 2013 Dec 2;13(6):638-45. Epub 2013 Oct 2.

University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2013.09.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5556922PMC
December 2013

Clearing the path for MPN therapy monitoring.

Authors:
Ruben A Mesa

Blood 2013 Nov;122(23):3704-5

MAYO CLINIC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2013-10-529990DOI Listing
November 2013

Emerging drugs for polycythemia vera.

Expert Opin Emerg Drugs 2013 Sep;18(3):393-404

Mayo College of Medicine, Mayo Clinic, Mayo Clinic Cancer Center, Division of Hematology & Medical Oncology, 13400 E. Shea Boulevard, Scottsdale, AZ 85259, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14728214.2013.832754DOI Listing
September 2013

Improving disease burden in myelofibrosis: changing the natural history of the disease.

Authors:
Ruben A Mesa

Oncology (Williston Park) 2013 Jul;27(7):715-6

Acute and Chronic Leukemias Program, Division of Hematology-Oncology, Mayo Clinic Cancer Center, Phoenix, Arizona, USA.

View Article

Download full-text PDF

Source
July 2013